01—Abstract
Summary
Summary of the 10-Q filed April 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company (LLY) reported robust financial results for the first quarter of 2024, with total revenue reaching $8.77 billiona, a significant 26% increase year-over-year.
This growth was largely driven by strong performance in key products like Mounjaro, Zepbound, Verzenio, and Jardiance, despite supply constraints for some incretin medicines. Net income surged by 67% to $2.24 billionb, translating to diluted earnings per share of $2.48, a 66% increase from the prior year's first quarter. The company continues to invest heavily in research and development, with R&D expenses increasing by 27% to $2.52 billion, reflecting its commitment to pipeline expansion.
Marketing, selling, and administrative expenses also saw an increase of 12%c. Despite increased operational costs, Eli Lilly demonstrated improved profitability, with gross margin as a percentage of revenue rising to 80.9%, up from 76.6% in the prior year's comparable quarter, attributed to favorable pricing and product mix. The company's financial position remains strong, with sufficient liquidity to fund operations and planned capital expenditures.
02—Key points
Key Highlights
- Revenue surged 26% year-over-year to $8.77 billion, driven by strong sales of Mounjaro, Zepbound, Verzenio, and Jardiance.
- Net income increased significantly by 67% to $2.24 billion, with diluted EPS rising 66% to $2.48.
- Gross margin improved to 80.9% of revenue, up from 76.6% in Q1 2023, due to higher realized prices and a favorable product mix.
- Research and Development (R&D) expenses increased by 27% to $2.52 billion, underscoring continued investment in the pipeline.
- Sales of Mounjaro and Zepbound (incretin medicines) showed substantial growth, though supply constraints remain a factor.
- Zepbound, launched in late 2023, generated $517.4 million in U.S. revenue in its first full quarter.
- The company issued $6.5 billion in fixed-rate notes in February 2024 to support general business purposes.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed April 30, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $8.77B$6.96B | +26.0% |
| Cost of Revenue | $1.67B$1.63B | +2.9% |
| Gross Profit | $7.09B$5.33B | +33.0% |
| SG&A Expenses | $1.95B$1.75B | +11.6% |
| Interest Expense | $179.60M$102.80M | +74.7% |
| Net Income | $2.24B$1.34B | +66.8% |
| EPS (Basic) | $2.49$1.49 | +67.1% |
| EPS (Diluted) | $2.48$1.49 | +66.4% |
| Shares Outstanding (Basic) | 900.80M901.00M | 0.0% |
| Shares Outstanding (Diluted) | 903.80M903.30M | +0.1% |
05—Questions
Frequently Asked Questions
What are the primary drivers of Eli Lilly's revenue growth in Q1 2024?
The primary drivers of Eli Lilly's revenue growth were increased sales volume and higher realized prices, particularly from Mounjaro®, Zepbound®, Verzenio®, and Jardiance®. The strong demand for its incretin medicines, Mounjaro and Zepbound, significantly contributed to the revenue increase, although supply constraints limited the full realization of this demand.
How is the company managing the supply constraints for its incretin medicines?
Eli Lilly is actively expanding manufacturing capacity to meet the high demand for its incretin medicines. They expect supply to remain tight in the short to mid-term, with sales growth primarily dependent on production volume. Measures include prioritizing existing patients and managing launch timing in new markets.
What is the company's outlook on research and development (R&D) spending?
Eli Lilly continues to prioritize and increase its R&D investment, with R&D expenses rising by 27% in Q1 2024. This reflects substantial investments in late-stage assets and early-stage research, indicating a strong commitment to developing new medicines.
How did the POINT Acquisition impact the financial results?
Eli Lilly acquired POINT Biopharma for $1.04 billion in December 2023. While the acquisition added goodwill and intangible assets, the results of operations attributable to POINT for the first quarter of 2024 were not material to the consolidated financial statements.
06—Continue